[Comparison of efficacy of pegylated interferon alfa-2a or interferon alfa-2b combination therapy with nucleus(t)ide analogues in HBeAg positive chronic hepatitis B patients].
作者信息
Wang Shu-qiang, Xu Kai-ju, Wu Jia-zhen, Liu Xiao-shu, Luo Ting-ting, Yang Ren-guo, Geng Xiao-xia, Huang Ren-gang, Lin Jian-mei, Jiang Nan
机构信息
Department of Infectious Diseases, Sichuan Academy of Medical Sciences, Chengdu, China.
出版信息
Zhonghua Gan Zang Bing Za Zhi. 2011 Oct;19(10):785-6.
PMID:22423366
Abstract
摘要
相似文献
1
[Comparison of efficacy of pegylated interferon alfa-2a or interferon alfa-2b combination therapy with nucleus(t)ide analogues in HBeAg positive chronic hepatitis B patients].
Zhonghua Gan Zang Bing Za Zhi. 2011 Oct;19(10):785-6.
2
Chronic hepatitis B: HBeAg seroconversion after pegylated interferon and nucleos(t)ide analogs.慢性乙型肝炎：聚乙二醇干扰素和核苷（酸）类似物治疗后的HBeAg血清学转换
Hepatology. 2005 Dec;42(6):1459; author reply 1459-60. doi: 10.1002/hep.20951.
3
Extended treatment with peginterferon α-2a in combination with lamivudine or adefovir for 96 weeks yields high rates of HBeAg and HBsAg seroconversion.延长聚乙二醇干扰素α-2a 联合拉米夫定或阿德福韦酯治疗 96 周可获得较高的 HBeAg 和 HBsAg 血清学转换率。
J Dig Dis. 2013 Aug;14(8):446-50. doi: 10.1111/1751-2980.12065.
4
A randomized, open-label clinical study of combined pegylated interferon Alfa-2a (40KD) and entecavir treatment for hepatitis B "e" antigen-positive chronic hepatitis B.聚乙二醇干扰素 Alfa-2a（40KD）联合恩替卡韦治疗乙型肝炎“e”抗原阳性慢性乙型肝炎的随机、开放标签临床研究。
Clin Infect Dis. 2014 Dec 15;59(12):1714-23. doi: 10.1093/cid/ciu702. Epub 2014 Sep 4.
5
Efficacy of sequential use of telbivudine in hepatitis B e antigen-positive chronic hepatitis B patients with partial responses to pegylated interferon: a pilot study.核苷（酸）类似物序贯治疗对聚乙二醇干扰素治疗部分应答的 HBeAg 阳性慢性乙型肝炎患者的疗效：一项初步研究。
J Viral Hepat. 2013 Apr;20 Suppl 1:52-7. doi: 10.1111/jvh.12064.
6
Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial.聚乙二醇化干扰素α-2b单药或联合拉米夫定治疗HBeAg阳性慢性乙型肝炎：一项随机试验
Lancet. 2005;365(9454):123-9. doi: 10.1016/S0140-6736(05)17701-0.
7
Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.聚乙二醇干扰素α-2a、拉米夫定及两者联合治疗HBeAg阳性慢性乙型肝炎
N Engl J Med. 2005 Jun 30;352(26):2682-95. doi: 10.1056/NEJMoa043470.
8
48 weeks pegylated interferon alpha-2a is superior to 24 weeks of pegylated interferon alpha-2b in achieving hepatitis B e antigen seroconversion in chronic hepatitis B infection.在慢性乙型肝炎感染中，48周聚乙二醇化干扰素α-2a在实现乙肝e抗原血清学转换方面优于24周聚乙二醇化干扰素α-2b。
Aliment Pharmacol Ther. 2006 Apr 15;23(8):1171-8. doi: 10.1111/j.1365-2036.2006.02887.x.
9
[HBeAg seroconversion achieved by sequential peginterferon alfa-2a therapy in chronic hepatitis B patients with unsatisfactory end point following entecavir treatment].[恩替卡韦治疗后终点不理想的慢性乙型肝炎患者序贯聚乙二醇干扰素α-2a治疗实现HBeAg血清学转换]
Zhonghua Gan Zang Bing Za Zhi. 2013 Jul;21(7):502-5. doi: 10.3760/cma.j.issn.1007-3418.2013.07.007.
10
Treatment of HBeAg-negative chronic hepatitis B with interferon or pegylated interferon.
J Hepatol. 2003;39 Suppl 1:S164-7. doi: 10.1016/s0168-8278(03)00329-5.
Zotero 插件